Related references
Note: Only part of the references are listed.A phase 2 clinical trialassessing theefficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer
Alice Y. Ho et al.
CANCER (2020)
Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020
Hamdy A. Azim et al.
BREAST JOURNAL (2020)
Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study
Junxian Li et al.
BREAST CANCER (2020)
E-cadherin deregulation in breast cancer
Giovanni Corso et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Role of Immunotherapy in Triple-Negative Breast Cancer
Tanya E. Keenan et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Targeting the Wnt/β-catenin signaling pathway in cancer
Ya Zhang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin et al.
BREAST CANCER RESEARCH (2020)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M. E. Robson et al.
ANNALS OF ONCOLOGY (2019)
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Shuang Qin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer
Sha Zhao et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Apatinib enhanced anti-tumor activity of cisplatin on triple-negative breast cancer through inhibition of VEGFR-2
Zhenyuan Gao et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
E-cadherin, Snail, ZEB-1, DNMT1, DNMT3A and DNMT3B expression in normal and breast cancer tissues
Shaian Tavakolian et al.
ACTA BIOCHIMICA POLONICA (2019)
Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers (vol 78, pg 747, 2018)
Lesley J. Scott
DRUGS (2018)
Genetic Markers in Triple-Negative Breast Cancer
Zuzana Sporikova et al.
CLINICAL BREAST CANCER (2018)
Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer
Hong-Dou Chen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer
Weigang Wang et al.
CLINICA CHIMICA ACTA (2017)
Serum Tumor Markers in Stage I-II Breast Cancer
Renato Tozzoli et al.
MEDICINAL CHEMISTRY (2016)
Apatinib for the treatment of gastric cancer
Giandomenico Roviello et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2016)
CA153 in Breast Secretions as a Potential Molecular Marker for Diagnosing Breast Cancer: A Meta Analysis
Shifu Tang et al.
PLOS ONE (2016)
Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer
Na Young Jang et al.
BMC CANCER (2015)
Subtyping of Triple-Negative Breast Cancer: Implications for Therapy
Vandana G. Abramson et al.
CANCER (2015)
Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretrnted patients with metastatic triple-negative breast cancer
Xichun Hu et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Expression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in breast cancers
Julia Y. S. Tsang et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
The prognostic impact of age in patients with triple-negative breast cancer
Cornelia Liedtke et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Share Paper
